Mircera approved for monthly dosing in ESA-naive patients

The renal anaemia treatment Mircera (methoxypolyethyleneglycol-epoetin beta) can now be administered once monthly in patients who are not on dialysis and are not currently receiving an erythropoiesis-stimulating agent. At this dosing interval, the recommended dose is 1.2 microgram/kg by subcutaneous injection.

The long-acting erythropoietin receptor activator was previously licensed only for fortnightly dosing in this population.

View Mircera drug record

Further information: Roche

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more